Magnetic resonance imaging · 2026
Dentate nucleus signal changes after multiple GBCAs MRI in breast cancer patients: A generalized additive model retrospective study.
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Wang Chuanbing, Jiang Yong, Liu Mengdi, Sha Xuan, Li Yang, Xu Ziqing, Wang Shouju, Tang Yuxia
Аннотация
BACKGROUND: While research has explored gadolinium retention differences between linear and macrocyclic GBCAs, comparative studies of structurally distinct linear subtypes (ionic vs. nonionic) in high-dose, large cohorts remain limited.
PURPOSE: To investigate factors influencing dentate nucleus (DN) signal increase on non-contrast T1WI after multiple GBCA administrations in breast cancer patients, focusing on contrast type (nonionic gadodiamide vs. ionic gadopentetate), interdose intervals, and adjuvant therapies.
STUDY TYPE: Cohort study.
POPULATION: 197 female breast cancer patients (excluded from 332) with ≥3 GBCA-enhanced scans and ≥ 2 non-enhanced cranial MRIs (2016-2023), mean age 51.5 years (26-78).
FIELD STRENGTH/SEQUENCE: 1.5 T and 3.0 T, turbo spin-echo inversion recovery sequence ASSESSMENT: Blinded DN/pons signal ratio measurements; relative change (Rchange) reflected gadolinium retention. Associations between Rchange and covariates (contrast type, intervals, therapies, etc.) were analyzed.
STATISTICAL TESTS: Generalized additive models (GAMs) and intraclass correlation coefficients (ICC).
RESULTS: 107 patients received gadodiamide (mean 7.17 administrations), 60 gadopentetate (mean 7.15), 30 Mixed GBCA (mean 6.80). Excellent interobserver agreement (ICC: 0.860-0.862). GAM showed higher Rchange in gadodiamide vs. gadopentetate (0.080 ± 0.041 vs 0.056 ± 0.034; 1.43-fold, P < 0.001). Rchange inversely correlated with interdose intervals (P < 0.001) and hormonal therapy (P = 0.021), with no associations with chemotherapy, targeted therapy, calcium supplementation, or age (all P > 0.05).
DATA CONCLUSION: Nonionic linear gadodiamide has higher intracranial gadolinium retention propensity than ionic linear gadopentetate. Interdose intervals and hormonal therapy are significant modulators.
PURPOSE: To investigate factors influencing dentate nucleus (DN) signal increase on non-contrast T1WI after multiple GBCA administrations in breast cancer patients, focusing on contrast type (nonionic gadodiamide vs. ionic gadopentetate), interdose intervals, and adjuvant therapies.
STUDY TYPE: Cohort study.
POPULATION: 197 female breast cancer patients (excluded from 332) with ≥3 GBCA-enhanced scans and ≥ 2 non-enhanced cranial MRIs (2016-2023), mean age 51.5 years (26-78).
FIELD STRENGTH/SEQUENCE: 1.5 T and 3.0 T, turbo spin-echo inversion recovery sequence ASSESSMENT: Blinded DN/pons signal ratio measurements; relative change (Rchange) reflected gadolinium retention. Associations between Rchange and covariates (contrast type, intervals, therapies, etc.) were analyzed.
STATISTICAL TESTS: Generalized additive models (GAMs) and intraclass correlation coefficients (ICC).
RESULTS: 107 patients received gadodiamide (mean 7.17 administrations), 60 gadopentetate (mean 7.15), 30 Mixed GBCA (mean 6.80). Excellent interobserver agreement (ICC: 0.860-0.862). GAM showed higher Rchange in gadodiamide vs. gadopentetate (0.080 ± 0.041 vs 0.056 ± 0.034; 1.43-fold, P < 0.001). Rchange inversely correlated with interdose intervals (P < 0.001) and hormonal therapy (P = 0.021), with no associations with chemotherapy, targeted therapy, calcium supplementation, or age (all P > 0.05).
DATA CONCLUSION: Nonionic linear gadodiamide has higher intracranial gadolinium retention propensity than ionic linear gadopentetate. Interdose intervals and hormonal therapy are significant modulators.